Gregory M. LaMonte

Gregory M. LaMonte

Auto-generated profile, based on publicly available information

Gregory M. LaMonte

Department of Pediatrics School of Medicine University of California San Diego 9500 Gilman Drive La Jolla California 92093 USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Chemistry – A European Journal
Verified
Journal Article
Closed access
JAjehad almaliti
jehad almaliti
PFPavla Fajtová
Pavla Fajtová
JCJaeson Calla
Jaeson Calla
GLGregory M. LaMonte
Gregory M. LaMonte
MFMudong Feng
Mudong Feng
AOAnthony ODonoghue
Anthony ODonoghue

7 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JAjehad almaliti
jehad almaliti
PFPavla Fajtová
Pavla Fajtová
JCJaeson Calla
Jaeson Calla
GLGregory M. LaMonte
Gregory M. LaMonte
MFMudong Feng
Mudong Feng
AOAnthony ODonoghue
Anthony ODonoghue
Here we present remarkable epoxyketone-based proteasome inhibitors with low nanomolar in vitro potency for blood-stage Plasmodium falciparum and low cytotoxicity for human cells. Our best compound has more than 2,600-fold greater selectivity for erythrocytic-stage P. falciparum over HepG2 cells, which is largely driven by the accommodation of the parasite proteasome for a d -amino acid in the P3 position and the preference for a difluorobenzyl group in the P1 position. These compounds also significantly reduce parasitemia in a P. berghei mouse infection model and prolong survival of animals by an average of 6 days. The current epoxyketone inhibitors are ideal starting compounds for orally bioavailable anti-malarial drugs.